AtriCure Shares Plunge 13.68% Despite Beating Revenue Estimates

AtriCure (ATRC) shares plummeted 13.68% today, marking the lowest level since October 2024, with an intraday decline of 17.34%.

AtriCure (ATRC) experienced a new low stock price of $30.94 on April 29, 2025. To backtest the impact of this event on future price movements, we analyzed the stock's performance over various periods:
One Week After the Low: The stock price increased by 2.64% to $31.66, indicating a short-term upward movement.
One Month After the Low: The stock price rose by 6.47% to $33.60, showing continued growth in the medium term.
Three Months After the Low: The stock price surged by 14.24% to $37.76, suggesting a strong recovery in the long term.
Conclusion: The impact of ATRC's stock price reaching a new low on future price movements was generally positive. The stock experienced increases in the short, medium, and long term following the low point. This indicates that investors may have seen opportunities in the stock at the low price, leading to a rebound in the price over the subsequent weeks and months. However, it's important to note that past performance is not always indicative of future results, and other factors could influence the stock's future movements.

AtriCure reported a loss of $0.14 per share for the first quarter of 2025, which was better than the Zacks Consensus Estimate of a loss of $0.25 per share. The company also exceeded revenue expectations, reporting $123.62 million, surpassing the consensus estimate of $122.92 million. This represents a 13.6% year-over-year revenue increase. Despite a negative net margin and return on equity, the company showed significant EBITDA improvement, driven by strong performance in pain and appendage management.

AtriCure shares have risen approximately 10.2% since the start of the year, outperforming the S&P 500. The company's earnings revisions trend is mixed, translating into a Zacks Rank #3 (Hold), indicating the shares are expected to perform in line with the market in the near future.